Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.390
-0.010 (-0.71%)
At close: Dec 5, 2025, 4:00 PM EST
1.410
+0.020 (1.44%)
After-hours: Dec 5, 2025, 7:05 PM EST
Zentalis Pharmaceuticals Revenue
Zentalis Pharmaceuticals had revenue of $26.87M in the twelve months ending September 30, 2025, down -33.76% year-over-year. In the year 2024, Zentalis Pharmaceuticals had annual revenue of $67.43M.
Revenue (ttm)
$26.87M
Revenue Growth
-33.76%
P/S Ratio
3.71
Revenue / Employee
$161,837
Employees
166
Market Cap
100.43M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ZNTL News
- 25 days ago - Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 3 months ago - Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 4 months ago - Zentalis (ZNTL) Q2 Loss Narrows 70% - The Motley Fool
- 4 months ago - Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - GlobeNewsWire